Genus Capital Management Inc. Sells 14,048 Shares of Insulet Corporation $PODD

Genus Capital Management Inc. trimmed its holdings in Insulet Corporation (NASDAQ:PODD) by 91.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,271 shares of the medical instruments supplier’s stock after selling 14,048 shares during the quarter. Genus Capital Management Inc.’s holdings in Insulet were worth $361,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Larson Financial Group LLC boosted its position in shares of Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares during the period. Elyxium Wealth LLC bought a new position in Insulet in the fourth quarter worth $28,000. Whittier Trust Co. of Nevada Inc. lifted its position in Insulet by 48.9% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 43 shares during the period. Measured Wealth Private Client Group LLC bought a new position in Insulet in the third quarter worth $49,000. Finally, Osterweis Capital Management Inc. bought a new position in Insulet in the second quarter worth $51,000.

Analysts Set New Price Targets

Several brokerages recently commented on PODD. TD Cowen cut Insulet from a “buy” rating to a “hold” rating and set a $294.00 target price for the company. in a research report on Monday, January 26th. Stifel Nicolaus reduced their target price on Insulet from $350.00 to $250.00 in a research report on Thursday, May 7th. William Blair began coverage on Insulet in a research report on Wednesday, May 20th. They issued an “outperform” rating for the company. Truist Financial reduced their target price on Insulet from $315.00 to $250.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Oppenheimer reduced their target price on Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Twenty-one research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Insulet has an average rating of “Moderate Buy” and an average price target of $254.96.

Insider Activity

In related news, Director Michael R. Minogue acquired 2,030 shares of the business’s stock in a transaction on Wednesday, February 25th. The stock was bought at an average cost of $246.23 per share, with a total value of $499,846.90. Following the completion of the acquisition, the director owned 17,483 shares in the company, valued at $4,304,839.09. The trade was a 13.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.36% of the company’s stock.

Insulet Price Performance

Shares of NASDAQ PODD opened at $154.87 on Tuesday. The stock has a market cap of $10.73 billion, a PE ratio of 36.02, a PEG ratio of 1.22 and a beta of 1.20. The business has a fifty day moving average of $189.91 and a two-hundred day moving average of $249.64. Insulet Corporation has a 52-week low of $145.59 and a 52-week high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business’s revenue was up 33.9% on a year-over-year basis. During the same period last year, the business earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities research analysts expect that Insulet Corporation will post 6.43 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.